LIFEVANTAGE CORP Deferred Revenue
LIFEVANTAGE CORP (LFVN) had Deferred Revenue of $1.74 million as of 2017-06-30, per its 10-K filed 2017-09-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2017-09-07
- 2017-06-30: Deferred Revenue, Current $1.74M.
- 2016-06-30: Deferred Revenue, Current $2.41M.
- 2015-06-30: Deferred Revenue, Current $990.00K.
- 2014-06-30: Deferred Revenue, Current $887.00K.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2017-06-30 | $1.74M 10-K · filed 2017-09-07 | |
| 2016-06-30 | $2.41M 10-K · filed 2017-09-07 | |
| 2015-06-30 | $990.00K 10-K · filed 2016-12-12 | |
| 2014-06-30 | $887.00K 10-K · filed 2015-09-01 | |
| 2013-06-30 | $545.00K 10-K · filed 2014-09-10 | $421.00K 10-K · filed 2013-09-12 |
| 2012-06-30 | $210.00K 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |